HPA008338

antibody from Atlas Antibodies

Targeting: HMGCR

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA008338

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA008338, RRID:AB_10960401

Product name

Anti-HMGCR

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human HMGCR, Gene description: 3-hydroxy-3-methylglutaryl-CoA reductase, Validated applications: IHC, Uniprot ID: P04035, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.1 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence

Wei S, Liu L, Chen Z, Yin W, Liu Y, Ouyang Q, Zeng F, Nie Y, Chen T
Journal of Cellular and Molecular Medicine 2019;24(1):276-284

---

SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression

Zhong C, Fan L, Li Z, Yao F, Zhao H
Molecular Medicine Reports 2019

---

Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.

Tryggvadottir H, Huzell L, Gustbée E, Simonsson M, Markkula A, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H
Frontiers in oncology 2018;8:428

---

Cilia loss sensitizes cells to transformation by activating the mevalonate pathway

Deng Y, Cai Z, Shi S, Jiang H, Shang Y, Ma N, Wang J, Guan D, Chen T, Rong Y, Qian Z, Zhang E, Feng D, Zhou Q, Du Y, Liu D, Huang X, Liu L, Chin E, Li D, Wang X, Zhang X, Xie D
Journal of Experimental Medicine 2018;215(1):177-195

---

Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.

Gray RT, Loughrey MB, Bankhead P, Cardwell CR, McQuaid S, O'Neill RF, Arthur K, Bingham V, McGready C, Gavin AT, James JA, Hamilton PW, Salto-Tellez M, Murray LJ, Coleman HG
British journal of cancer 2017 Jun 6;116(12):1652-1659

---

HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes

Di Benedetto A, Mottolese M, Sperati F, Ercolani C, Di Lauro L, Pizzuti L, Vici P, Terrenato I, Shaaban A, Sundara-Rajan S, Humphries M, Barba M, Speirs V, De Maria R, Maugeri-Saccà M
Scientific Reports 2016;6(1)

---

High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer.

Kimbung S, Lettiero B, Feldt M, Bosch A, Borgquist S
Oncotarget 2016 Sep 13;7(37):59640-59651

---

Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.

Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, Rose C, Ingvar C, Borgquist S, Jernström H
BMC clinical pathology 2015;15:8

---

HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.

Bengtsson E, Nerjovaj P, Wangefjord S, Nodin B, Eberhard J, Uhlén M, Borgquist S, Jirström K
Diagnostic pathology 2014 Apr 7;9:78

---

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial

Bjarnadottir O, Romero Q, Bendahl P, Jirström K, Rydén L, Loman N, Uhlén M, Johannesson H, Rose C, Grabau D, Borgquist S
Breast Cancer Research and Treatment 2013;138(2):499-508